No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
PRRUF IMMUTEP LTD
- 0.204
- 0.0000.00%
15min DelayClose Nov 12 16:00 ET
296.66MMarket Cap-9.27P/E (TTM)
0.000High0.000Low0Volume0.000Open0.204Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)1.45BShares0.28452wk High2.49P/B291.04MFloat Cap0.17352wk Low--Dividend TTM1.43BShs Float0.284Historical High--Div YieldTTM0.00%Amplitude0.173Historical Low--Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Bell Potter Maintains IMMUTEP LTD(PRRUF.US) With Buy Rating, Cuts Target Price to $0.47
Bell Potter analyst Thomas Wakim maintains $IMMUTEP LTD(PRRUF.US)$ with a buy rating, and adjusts the target price from $0.51 to $0.47.According to TipRanks data, the analyst has a success rate of 15.
CCORF Maintains IMMUTEP LTD(PRRUF.US) With Buy Rating, Maintains Target Price $0.64
CCORF analyst Elyse Shapiro maintains $IMMUTEP LTD(PRRUF.US)$ with a buy rating, and maintains the target price at $0.64.According to TipRanks data, the analyst has a success rate of 30.4% and a
Jefferies Maintains IMMUTEP LTD(PRRUF.US) With Buy Rating, Raises Target Price to $0.74
Jefferies analyst David Stanton maintains $IMMUTEP LTD(PRRUF.US)$ with a buy rating, and adjusts the target price from $0.63 to $0.74.According to TipRanks data, the analyst has a success rate of 63.4
US stocks fluctuate | Immutep up nearly 23% before the market, showing excellent performance in the treatment of new cancer.
On July 12th, Gelunhui reported that biotechnology company Immutep (IMMP.US) rose 22.89% before the market, with a price of $2.45. According to the news, the company stated that the TACTI-003 Phase 2b trial group B achieved 'positive' results. The trial evaluated the first-line treatment potential of the company's eftilagimod alfa in combination with Merck's Keytruda for patients with recurrent or metastatic squamous cell carcinoma of the head and neck who had negative expression of PD-L1. Based on the results, the combination therapy achieved an objective response rate of 35.5% and a
Bell Potter Maintains IMMUTEP LTD(PRRUF.US) With Buy Rating, Raises Target Price to $0.5
Bell Potter analyst Thomas Wakim maintains $IMMUTEP LTD(PRRUF.US)$ with a buy rating, and adjusts the target price from $0.43 to $0.5.According to TipRanks data, the analyst has a success rate of 20.0
CCORF Maintains IMMUTEP LTD(PRRUF.US) With Buy Rating, Cuts Target Price to $0.64
CCORF analyst Elyse Shapiro maintains $IMMUTEP LTD(PRRUF.US)$ with a buy rating, and adjusts the target price from $0.66 to $0.63.According to TipRanks data, the analyst has a success rate of 28.9% an
Trending Stocks
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.